After obtaining formal institutional review board approval, the charts of 441 patients from 1996 to 2005 receiving low-dose-rate brachytherapy for prostate ... to offer androgen ablation was ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

placing it second behind lung cancer as the leading cause of cancer death among American males. The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

We systematically searched PubMed, Scopus, Embase, and Cochrane databases for randomized clinical trials that compared definitive radiotherapy with or without ADT in localized prostate cancer. The ...

A report into recurrent prostate cancer by Figg et al ... time to PSA progression seems to occur after two courses of androgen ablation, which might correspond to the time for the evolution ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...